Levodopa/benserazide
| Combination of | |
|---|---|
| Levodopa | Dopamine agonist |
| Benserazide | Decarboxylase inhibitors |
| Clinical data | |
| Trade names | Prolopa, Madopar, others[1] |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Levodopa/benserazide, sold under the brand name Prolopa among others, is a fixed-dose combination medication used for the treatment of Parkinson's disease.[2][3][4]
Medical uses
[edit]Levodopa/benserazide is indicated for the treatment of Parkinson's disease with the exception of drug-induced parkinsonism.[2][3][4]
References
[edit]- ^ "Levodopa".
- ^ a b c d "Madopar Product Information". Medsinfo. 8 July 2019. Retrieved 2 September 2024.
- ^ a b c "Prolopa Product information". Health Canada. 25 April 2012. Retrieved 8 January 2023.
- ^ a b c "Madopar 100 mg/25 mg Dispersible Tablets - Summary of Product Characteristics (SmPC)". (emc). 8 April 2020. Retrieved 9 January 2023.
External links
[edit]
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |